Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ensysce Biosciences, Inc. (ENSC : NSDQ)

• Company Description    Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $0.32 Daily Weekly Monthly 20 Day Moving Average: 5,258,645 shares Shares Outstanding: 14.69 (millions) Market Capitalization: $4.68 (millions) Beta: 0.87 52 Week High: $2.75 52 Week Low: $0.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.86% -28.53% 12 Week -19.34% -25.44% Year To Date -65.37% -67.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7946 IVANHOE AVENUE SUITE 201 - LA JOLLA,CA 92037 USA ph: 858-263-4196 fax: - shannon@mzgroup.us http://www.ensysce.com

• General Corporate Information    Officers Lynn Kirkpatrick - Chief Executive Officer; President and Director Bob Gower - Chairman and Director David Humphrey - Chief Financial Officer; Secretary and Treasurer William Chang - Director Adam Levin - Director Peer Information Ensysce Biosciences, Inc. (CORR.) Ensysce Biosciences, Inc. (RSPI) Ensysce Biosciences, Inc. (CGXP) Ensysce Biosciences, Inc. (BGEN) Ensysce Biosciences, Inc. (GTBP) Ensysce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 293602504 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 14.69 Most Recent Split Date: 12.00 (0.07:1) Beta: 0.87 Market Capitalization: $4.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.54 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.99 EPS Growth vs. Year Ago Period: 62.59% vs. Previous Quarter: 30.67% Sales Growth vs. Year Ago Period: -27.20% vs. Previous Quarter: -48.94% ROE 03/31/26 - -766.45 12/31/25 - -426.62 09/30/25 - -437.31 ROA 03/31/26 - -256.59 12/31/25 - -195.53 09/30/25 - -231.45 Current Ratio 03/31/26 - 0.71 12/31/25 - 1.59 09/30/25 - 1.27 Quick Ratio 03/31/26 - - 12/31/25 - 1.59 09/30/25 - 1.27 Operating Margin 03/31/26 - -250.39 12/31/25 - -200.87 09/30/25 - -244.47 Net Margin 03/31/26 - -250.39 12/31/25 - -200.87 09/30/25 - -244.47 Pre-Tax Margin 03/31/26 - -250.39 12/31/25 - -200.83 09/30/25 - -244.50 Book Value 03/31/26 - -0.05 12/31/25 - 0.63 09/30/25 - 0.29 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©